F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer

NCT00602043 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

NIH

Sponsor class

Conditions

Estrogen Receptor-positive Breast Cancer
Progesterone Receptor-negative Breast Cancer
Progesterone Receptor-positive Breast Cancer
Recurrent Breast Cancer
Stage IV Breast Cancer

Interventions

RADIATION: F-18 16 alpha-fluoroestradiol
RADIATION: fludeoxyglucose F 18
PROCEDURE: positron emission tomography
PROCEDURE: positron emission tomography
PROCEDURE: computed tomography
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)